Metrics as of 10/15/2026, 12:00 PM (Berlin time), refresh in progress.
Minerva Neurosciences Stock
Minerva Neurosciences, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Remy Luthringer
- Employees
- 7
- Market cap
- $112 M
- IPO
- 01/07/2014
Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an…
Minerva Neurosciences stock: price history
1D
-2.9%
1W
-26.1%
1M
-32.7%
6M
-65.1%
YTD
-41.5%
1Y
-7.1%
2Y
-12.0%
5Y
-78.2%
10Y
-97.6%
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~57% stronger price swings than usual
Ask the agents about Minerva Neurosciences
Analyst assessment of Minerva Neurosciences
PRICE TARGET LOW
US$10.00
CONSENSUS
US$10.00
MEDIAN
US$10.00
PRICE TARGET HIGH
US$10.00
0
STRONG BUY
5
BUY
2
HOLD
0
SELL
0
STRONG SELL
7
TOTAL · Buy
As of: 14/08/2026
Minerva Neurosciences stock metrics
P/E
-0.08
P/B
-0.54
EV/EBITDA
-0.22
RETURN ON EQUITY
-8.7%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
78.9%
FLOAT SHARES
37,684,220
AVG. DAILY VOLUME (30D)
151,042
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Minerva Neurosciences stock
What does Minerva Neurosciences do?
Minerva Neurosciences, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Remy Luthringer, the company employs around 7 people.
The IPO was on 01/07/2014; the stock trades on NASDAQ under the ticker NERV.
What do analysts say about Minerva Neurosciences stock?
7 analysts rate the stock, the consensus is Buy (as of 14/08/2026).
The average price target is US$10.00, ranging from US$10.00 to US$10.00, with a median of US$10.00.
This is an external assessment, not a statement by Market Jury.
When does Minerva Neurosciences report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly 57% stronger than usual.
Does Minerva Neurosciences pay a dividend?
No, Minerva Neurosciences currently does not pay a dividend.
Which stocks are comparable to Minerva Neurosciences?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Minerva Neurosciences stock analyzed?
Clicking "Analyze stock" lets five strategies assess Minerva Neurosciences against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.